Premature births are intimately linked with inflammation of the uterine tissue, a biological response which induces contractions and preterm labor. In their search for a mean to prevent this phenomenon and complications related to deliveries occurring before 37 weeks of gestation, researchers at CHU Sainte-Justine and University of Montreal discovered an agent that shows efficacy in inhibiting inflammation and preventing or delaying uterine contractions and premature delivery in murine models – without adversely affecting the fetus or the mother. This discovery is a giant step towards preventing prematurity, which is the world's leading cause of infant death and the origin of potentially severe, long-lasting physical, intellectual or psychological impairment for the 10% of infants born preterm world-wide.